Literature DB >> 28726123

Rapidly Progressive White Matter Involvement in Early Childhood: The Expanding Phenotype of Infantile Onset Pompe?

A Broomfield1, J Fletcher2, P Hensman3, R Wright4, H Prunty5, J Pavaine6, S A Jones2.   

Abstract

Glycogen accumulation in the central nervous system of patients with classical infantile onset Pompe disease (IOPD) has been a consistent finding on the few post-mortems performed. While delays in myelination and a possible reduction in processing speed have previously been noted, it has only been recently that the potential for clinically significant progressive white matter disease has been noted. The limited reports thus far published infer that in some IOPD patients, this manifests as intellectual decline in the second decade of life. We present a CRIM negative patient, immunomodulated with rituximab and methotrexate at birth, who despite an initial good clinical response to ERT, at the age of just under 4 years, presented with evolving spasticity in the lower limbs. The investigation of which revealed progressive central nervous system involvement. Given both the earlier onset of the symptoms and consanguineous familial pedigree, extensive biochemical and genetic investigation was undertaken to ensure no alternative pathology was elucidated. In light of these findings, we review the radiology and post-mortems of previous cases and discuss the potential mechanisms that may underlie this presentation.

Entities:  

Keywords:  CRIM negative; Enzyme replacement therapy; Glycogen; Infantile onset Pompe disease; Lysosomal storage; White matter disease

Year:  2017        PMID: 28726123      PMCID: PMC5953890          DOI: 10.1007/8904_2017_46

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  31 in total

1.  Detection of a homozygous D645E mutation of the acid alpha-glucosidase gene and glycogen deposition in tissues in a second-trimester fetus with infantile glycogen storage disease type II.

Authors:  Chih-Ping Chen; Shuan-Pei Lin; Chin-Yuan Tzen; Fuu-Jen Tsai; Wuh-Liang Hwu; Wayseen Wang
Journal:  Prenat Diagn       Date:  2004-03       Impact factor: 3.050

2.  Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy.

Authors:  B J Ebbink; F K Aarsen; C M van Gelder; J M P van den Hout; N Weisglas-Kuperus; J Jaeken; M H Lequin; W F M Arts; A T van der Ploeg
Journal:  Neurology       Date:  2012-04-25       Impact factor: 9.910

Review 3.  Case definition and classification of leukodystrophies and leukoencephalopathies.

Authors:  Adeline Vanderver; Morgan Prust; Davide Tonduti; Fanny Mochel; Heather M Hussey; Guy Helman; James Garbern; Florian Eichler; Pierre Labauge; Patrick Aubourg; Diana Rodriguez; Marc C Patterson; Johan L K Van Hove; Johanna Schmidt; Nicole I Wolf; Odile Boespflug-Tanguy; Raphael Schiffmann; Marjo S van der Knaap
Journal:  Mol Genet Metab       Date:  2015-01-29       Impact factor: 4.797

4.  Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2.

Authors:  C Martini; G Ciana; A Benettoni; F Katouzian; G M Severini; R Bussani; B Bembi
Journal:  Neurology       Date:  2001-09-11       Impact factor: 9.910

5.  Conditional ablation of raptor or rictor has differential impact on oligodendrocyte differentiation and CNS myelination.

Authors:  Kathryn K Bercury; JinXiang Dai; Hilary H Sachs; Jared T Ahrendsen; Teresa L Wood; Wendy B Macklin
Journal:  J Neurosci       Date:  2014-03-26       Impact factor: 6.167

6.  Brain development in infantile-onset Pompe disease treated by enzyme replacement therapy.

Authors:  Yin-Hsiu Chien; Ni-Chung Lee; Shinn-Forng Peng; Wuh-Liang Hwu
Journal:  Pediatr Res       Date:  2006-07-20       Impact factor: 3.756

7.  Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants.

Authors:  Priya S Kishnani; Paula C Goldenberg; Stephanie L DeArmey; James Heller; Danny Benjamin; Sarah Young; Deeksha Bali; Sue Ann Smith; Jennifer S Li; Hanna Mandel; Dwight Koeberl; Amy Rosenberg; Y-T Chen
Journal:  Mol Genet Metab       Date:  2010-01       Impact factor: 4.797

Review 8.  Pompe disease: from pathophysiology to therapy and back again.

Authors:  Jeong-A Lim; Lishu Li; Nina Raben
Journal:  Front Aging Neurosci       Date:  2014-07-23       Impact factor: 5.750

9.  Modulation of mTOR signaling as a strategy for the treatment of Pompe disease.

Authors:  Jeong-A Lim; Lishu Li; Orian S Shirihai; Kyle M Trudeau; Rosa Puertollano; Nina Raben
Journal:  EMBO Mol Med       Date:  2017-03       Impact factor: 12.137

10.  Diagnosis, investigation and management of hereditary spastic paraplegias in the era of next-generation sequencing.

Authors:  Anke Hensiek; Stephen Kirker; Evan Reid
Journal:  J Neurol       Date:  2014-12-06       Impact factor: 4.849

View more
  6 in total

Review 1.  An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond.

Authors:  Aditi Korlimarla; Jeong-A Lim; Priya S Kishnani; Baodong Sun
Journal:  Ann Transl Med       Date:  2019-07

Review 2.  Long-term outcome and unmet needs in infantile-onset Pompe disease.

Authors:  Andreas Hahn; Anne Schänzer
Journal:  Ann Transl Med       Date:  2019-07

3.  Cell type-selective targeted delivery of a recombinant lysosomal enzyme for enzyme therapies.

Authors:  Andrew D Baik; Philip Calafati; Xiaoli Zhang; Nina A Aaron; Antonia Mehra; Sven Moller-Tank; Lawrence Miloscio; Maria Praggastis; Nicholas Giovannone; Cheryl Pan; Yajun Tang; Susannah Bridges; Alejo Mujica; Peter Barbounis; Jean Yanolatos; Nicholas Gale; Ning Li; Christos A Kyratsous; Christopher J Schoenherr; Andrew J Murphy; Aris N Economides; Katherine D Cygnar
Journal:  Mol Ther       Date:  2021-08-14       Impact factor: 11.454

4.  Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy.

Authors:  Paul T McIntosh; Lisa D Hobson-Webb; Zoheb B Kazi; Sean N Prater; Suhrad G Banugaria; Stephanie Austin; Raymond Wang; David S Enterline; Donald P Frush; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2017-10-13       Impact factor: 4.797

5.  Novel approaches to quantify CNS involvement in children with Pompe disease.

Authors:  Aditi Korlimarla; Gail A Spiridigliozzi; Kelly Crisp; Mrudu Herbert; Steven Chen; Michael Malinzak; Mihaela Stefanescu; Stephanie L Austin; Heidi Cope; Kanecia Zimmerman; Harrison Jones; James M Provenzale; Priya S Kishnani
Journal:  Neurology       Date:  2020-06-09       Impact factor: 9.910

Review 6.  Gene Therapy Developments for Pompe Disease.

Authors:  Zeenath Unnisa; John K Yoon; Jeffrey W Schindler; Chris Mason; Niek P van Til
Journal:  Biomedicines       Date:  2022-01-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.